Liver International

• HCC in Patients With NAFLD Without Cirrhosis This study compared the clinical characteristics of patients with non-cirrhotic NAFLD-HCC to those with cirrhosis. Do outcomes differ between the two groups?
  Liver International, July 2019
• Autoimmune Hepatitis: Current and Future Therapeutic Options This review summarizes current as well as promising investigational options for autoimmune hepatitis, a rare immune-mediated liver disease.
  Liver International, July 2019
• Treatment With DAAs for HCV and Risk of HCC This study indicates that the risk of hepatocellular carcinoma remains high in HCV patients with advanced fibrosis, even after achieving viral eradication with DAAs.
  Liver International, June 2019
• SVR and Long-term Glycemic Control in Patients With T2DM+HCV Successful HCV treatment among patients with type 2 diabetes significantly reduces HbA1c shortly after treatment. Are these reductions sustained over time?
  Liver International, June 2019
• Outcomes in HBV-related Acute on Chronic Liver Failure This study compared the 5-year survival rate and incidence rate of hepatocellular carcinoma between patients with HBV-related acute on chronic liver failure and HBV cirrhosis.
  Liver International, June 2019
• HCV Late Relapse in Patients With DAA-related SVR at Week 12 What are the clinical, epidemiological and virological features of patients who experience late relapse after successful treatment with direct-acting antivirals?
  Liver International, June 2019
• Drug-induced Liver Injury With Skin Reactions This review explores factors causing concomitant drug-induced skin and liver injury. What are the characteristics of liver involvement in patients with severe cutaneous adverse reaction?
  Liver International, May 2019
• AF: Highly Prevalent Yet Undertreated in Patients With NASH This study found that the prevalence of atrial fibrillation in patients with NASH is twice that of the general population. Are these patients receiving appropriate anticoagulation therapy?
  Liver International, May 2019
• When Is Stopping Immunosuppressives in AIH Justified How long should immunosuppressive treatment of autoimmune hepatitis be continued, and which patients are suitable for drug withdrawal?
  Liver International, May 2019
• Parental NAFLD Increases Risk of NAFLD in Offspring Are individuals with a parental history of hepatic steatosis at increased risk for NAFLD?
  Liver International, May 2019
• Metformin and Survival in Hepatocellular Carcinoma How might treatment with metformin influence survival in patients with hepatocellular carcinoma and T2DM?
  Liver International, April 2019
• Association Between NAFLD and Risk of AF in Adults This study aimed to provide a quantitative estimate of the magnitude of the association between NAFLD and risk of atrial fibrillation in the middle-aged and elderly.
  Liver International, April 2019
• Causality Between NAFLD and Risk of CVD and Type 2 Diabetes This study explores the evidence for a possible causal relationship between non-alcoholic fatty liver disease and type 2 diabetes or cardiovascular disease.
  Liver International, April 2019
• HCV Eradication and Transition of Preclinical HCC to HCC Does HCV eradication by direct-acting antivirals influence the transition of pre-clinical to clinical hepatocellular carcinoma?
  Liver International, April 2019
• Effect of PPIs on Risk, Prognosis of Infections in Cirrhosis Does the use of proton pump inhibitors increase the risk of bacterial infections or worsen their outcome in patients with cirrhosis and ascites?
  Liver International, March 2019
• Hepatitis C: Is Eradication Possible? Despite the availability of highly effective direct-acting antiviral therapeutic regimens, many barriers to HCV eradication persist.
  Liver International, March 2019
• CKD and Increased Mortality in Patients With NAFLD This study assessed the association between different stages of chronic kidney disease and mortality in patients with nonalcoholic fatty liver disease.
  Liver International, March 2019
• Predictors of NASH and Fibrosis in Non-obese NAFLD This study aimed to identify risk factors for nonalcoholic steatohepatitis and fibrosis in NAFLD. How do clinical and histological characteristics differ between obese and non-obese patients?
  Liver International, March 2019
• Factors Influencing Delayed Onset of Symptoms in DILI Why do some instances of drug-induced liver injury manifest days or weeks after drug cessation?
  Liver International, February 2019
• Features of He Shou Wu-induced Liver Injury He Shou Wu, a Chinese herb used since ancient times as an anti-aging remedy and all-around health tonic, can result in severe, sometimes fatal liver injury.
  Liver International, February 2019